Inyx And BioProgress Form Strategic Collaboration

New York, NY - Inyx, Inc., a pharmaceutical company focused on niche drug-delivery technologies and products, announced recently that its wholly owned, United Kingdom-based subsidiary, Inyx Pharma Limited, has entered into a strategic collaboration with BioProgress plc,an innovative specialty pharma and healthcare company with U.K. headquarters in Cambridge, England.

Under the collaboration, Inyx will provide assistance to broadly commercialize BioProgress' TABWRAP(TM) technology. TABWRAP(TM) is a patented, continuous process for delivering tablets or caplets in an ingestible or edible film sheet. It is applicable to a broad range of product applications, including prescription and over-the-counter pharmaceuticals.

Jack Kachkar, M.D., Chairman and CEO of Inyx, Inc., said, "We are pleased that BioProgress has selected to team up with Inyx to assist in the validation requirements and commercialization of its TABWRAP(TM) technology. We look forward to a growing collaboration with BioProgress."

Richard Trevillion, Chief Executive Officer of BioProgress, said, "Inyx has a long history of assisting companies and innovative pharmaceutical technologies with the required regulatory approvals on production processes and controls. We are confident that BioProgress will be able to accelerate its own development plan during 2007 through this strategic alliance with Inyx."

SOURCE: BioProgress and Inyx